Timur Yarovinsky

Vice President, Discovery, Director of Immunology at CaroGen Corporation

Role: Vice President, Discovery at Carogen Corporation
Location: New Haven, CT, US
LinkedIn followers: 500 followers

General Business & ManagementView LinkedIn profile

About Timur Yarovinsky

A team leader and drug developer with focus on immunotherapy of infectious diseases and cancer.

Experience

Vice President, Discovery
Carogen Corporation
Nov 2022 — Present
I oversee the preclinical development of CaroGen\'s portfolio of virus-like vesicles for immunotherapy of chronic hepatitis B and cancer.

Education

The Russian State Medical University
Doctor of Medicine (MD), Laboratory Medicine (Biophysics)
1994 — 1998
The Russian State Medical University
Doctor of Philosophy (PhD), Allergy and Immunology
1994 — 1997

Skills

In Vivo
Cell Biology
Multi-Color Flow Cytometry
Confocal Microscopy
Protein Expression
Western Blotting
Molecular Cloning
Animal Models
Biochemistry
Microscopy
Immunoprecipitation
Molecular Biology
Fluorescence Microscopy
Cell
Biophysics
Site-Directed Mutagenesis
Tissue Culture
Immunohistochemistry
Qpcr
Transfection

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email (2)
t••••••••@carogencorp.com
Personal email
•••••@•••••.com
Direct dial
+13•••••••52

Unlock verified contacts

Free to start · No credit card required

Current company

Carogen Corporation

Biotechnology · 10 employees · Founded 2012 · Farmington, Connecticut, United States

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases. Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.

carogencorp.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.